CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 112 enrolled
Drug / intervention
Conberceptdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02816710
NCT02816710Phase 4Completed
CompareCT.gov

Different Conbercept Injection Methods in Treatment of Severe Proliferative Diabetic Retinopathy

Ruijin Hospital·interventional·Posted Jun 28, 2016·Updated Nov 21, 2019

In Brief

A Phase 4 clinical trial evaluating Conbercept for Proliferative Diabetic Retinopathy and Tractional Retinal Detachment. Completed, enrolled 112 participants across 1 site.

Detailed Summary

To evaluate efficacy of different intravitreal Conbercept injection therapy in the treatment of severe proliferative diabetic retinopathy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProliferative Diabetic Retinopathy, Tractional Retinal Detachment
CountriesChina
Collaborators--

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 28, 2016
Enrollment StartJul 1, 2016
Primary CompletionSep 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 10.0 years ago

Interventions

Conberceptdrug

Conbercept is a humanized soluble fusion protein which has a high binding affinity to the Fc region of human immunoglobulin G1 simultaneously. Prior clinical studies have demonstrated that intravitreal conbercept (IVC) inhibits the process of angiogenesis in vivo and in vitro, and has been recognized as a novel effective treatment strategy for neovascularization, providing an alternative treatment option for ophthalmologists.